Compare OneSpan Inc (OSPN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Recursion Pharmaceuticals Inc — how do they compare? OneSpan Inc trades at $17.96 (market cap $652.28M), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.5× OneSpan Inc's market cap, and OneSpan Inc pays a 2.94% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| OSPN | RXRX | |
|---|---|---|
Market Cap | $652.28M | $2.31B |
Volume | 590,167 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $18.42 | $6.79 |
52-Week Low | $10.15 | $2.84 |
Typical Hold Time | 18 Days | 22 Days |
Enterprise Value | $621.36M | $1.83B |
Dividend Yield | 2.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $17.70, down 3.7% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 27.76% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights investor attention and a new product launch, DigipassONE, aimed at authentication modernization.
The outlook remains positive given consistent earnings beats and a strong analyst buy consensus, though risks include negative net cash flow trends and competitive pressures in the technology sector. Revenue growth is modest, but high margins and a reasonable P/E of 10 support valuation. The stock presents a value opportunity with controlled risk.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
